232 Clinical and health status assessments in anaemic chronic lymphocytic leukemia (CLL) patients treated with epoetin alfa

No abstract is available for this paper.

• Publication year

  1995

• Venue

  European Journal of Cancer

• Publication date

  1995-11-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/0959-8049(95)95490-W
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• La anemia en la leucemia linfática crónica: ¿es la eritropoyetina la solución del problema?

  2017cites this paper
• Effects of erythropoiesis-stimulating agents on fatigue- and anaemia-related symptoms in cancer patients: systematic review and meta-analyses of published and unpublished data

  2014cites this paper
• Venous thromboembolism risk and erythropoiesis-stimulating agents for the treatment of cancer-associated anemia: a meta-analysis

  2013cites this paper
• Cancer, meta-analysis and reporting biases: the case of erythropoiesis-stimulating agents.

  2013cites this paper
• Effects of erythropoiesis-stimulating agents on survival and other outcomes in patients with lymphoproliferative malignancies: a study-level meta-analysis

  2012cites this paper
• Erythropoietin or darbepoetin for patients with cancer.

  2012cites this paper
• Non-Hodgkin's Lymphoma Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and randomized multicenter study. The European Study Group of patients with multiple myeloma and non-Hodgkin's lymphoma--a Recombinant human erythropoietin in transfusion-dependent anemic

  2011cites this paper
• Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes

  2010cites this paper
• Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.

  2009cites this paper
• Erythropoietin or Darbepoetin for patients with cancer--meta-analysis based on individual patient data.

  2009cites this paper
• Benefits and harms of erythropoiesis-stimulating agents for anemia related to cancer: a meta-analysis

  2009cites this paper
• Epoetin treatment of anemia associated with multiple myeloma and non-Hodgkin’s lymphoma

  2008cites this paper
• The use of erythropoiesis-stimulating agents in patients with non-myeloid hematological malignancies: a systematic review

  2008influential citation
• Safety update on erythropoiesis-stimulating agents: trials within and outside the accepted indications.

  2008cites this paper
• Treatment options for anemia, taking risks into consideration: erythropoiesis-stimulating agents versus transfusions.

  2008cites this paper
• Venous thromboembolic events and erythropoiesis-stimulating agents: an update.

  2008cites this paper
• Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia.

  2008cites this paper
• Treatment for Anemia with Erythropoietic Agents in Patients with non- Myeloid Hematological Malignancies: A Clinical Practice Guideline

  2007cites this paper
• Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients.

  2006cites this paper
• Quality of life in chronic lymphocytic leukemia: A neglected issue

  2005cites this paper
• Recombinant human erythropoietin and overall survival in cancer patients: results of a comprehensive meta-analysis.

  2005cites this paper
• Management of cancer-related anemia with erythropoietic agents: doubts, certainties, and concerns.

  2005cites this paper
• Treatment of anemia with erythropoietic agents in patients with hematologic malignancies.

  2005cites this paper
• Anaemia in Cancer Patients

  2005cites this paper
• Role of Cytokines in the Management of Chronic Lymphocytic Leukemia

  2004cites this paper
• The Natural History of CLL

  2004cites this paper
• Epoetin alfa therapy for patients with hematologic malignancies and mild anemia.

  2003cites this paper
• The Efficacy of rHuEPO in Cancer‐Related Anaemia

  2003cites this paper
• Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.

  2002cites this paper
• Anemia of hematologic malignancies: what are the treatment options?

  2002cites this paper
• Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology.

  2002cites this paper
• Systematic review of controlled trials on erythropoietin to support evidence-based guidelines.

  2002cites this paper
• Epoetin alfa as a supportive measure in hematologic malignancies.

  2002cites this paper
• Advancing the treatment of hematologic malignancies through the development of targeted interventions.

  2002cites this paper
• B‐chronic lymphocytic leukemia: practical aspects

  2002cites this paper
• Management of disease-related anemia in patients with multiple myeloma or chronic lymphocytic leukemia: epoetin treatment recommendations.

  2002cites this paper
• Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy

  2002cites this paper
• Recombinant human erythropoietin (rhEPO) in anemia associated with multiple myeloma and non-Hodgkin’s lymphoma

  2002cites this paper
• REVIEW ARTICLE B-CHRONIC LYMPHOCYTIC LEUKEMIA: PRACTICAL ASPECTS

  2002cites this paper
• Erythropoietin: a paradigm for the development of practice guidelines.

  2001cites this paper
• Recombinant human erythropoietin in the treatment of anemic patients with hematological malignancies

  2001cites this paper
• Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing.

  2001cites this paper
• A Risk-Benefit Assessment of Epoetin in the Management of Anaemia Associated with Cancer

  1998cites this paper
• Recombinant human erythropoietin in transfusion-dependent anemic patients with multiple myeloma and non-Hodgkin's lymphoma--a randomized multicenter study. The European Study Group of Erythropoietin (Epoetin Beta) Treatment in Multiple Myeloma and Non-Hodgkin's Lymphoma.

  1996cites this paper